Evidence map›Paper›PMID 39255305›Full record

ArticlePloS one2024

Multivalency drives interactions of alpha-synuclein fibrils with tau.

Jennifer Ramirez, Ibrahim G Saleh, Evan S K Yanagawa, Marie Shimogawa, Emily Brackhahn, E James Petersson, Elizabeth Rhoades

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jennifer RamirezBiochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Ibrahim G SalehDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0009-0003-3263-7671
Evan S K YanagawaDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Marie ShimogawaDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-8471-9375
Emily BrackhahnDepartment of Chemistry, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-3775-1989
E James PeterssonBiochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
Elizabeth RhoadesBiochemistry and Molecular Biophysics Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.ORCID 0000-0002-1741-0650

Funding

Structural basis and physiological consequences of alpha-Synuclein binding to neurexin 1betaR01NS120625 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI RHOADES, ELIZABETH · 2021 to 2025
$2.9M
Predoctoral Training at the Chemistry-Biology InterfaceT32GM133398 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI Ronen Marmorstein, Ernest James Petersson · 2020 to 2026
$2.4M
Studying Aggregation in Neurodegenerative Disease Using Synthetic ProteinsR01NS103873 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI Ernest James Petersson · 2019 to 2026
$2.1M
Studying Aggregation in Neurodegenerative Disease using Synthetic ProteinsRF1NS103873 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI PETERSSON, ERNEST JAMES · 2023 to 2023
$1.8M
Combinatorial effects of PTMs on a-Synuclein structure, function and aggregationRF1NS125770 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI PETERSSON, ERNEST JAMES, RHOADES, ELIZABETH · 2022 to 2022
$1.7M
Bruker RapifleX MALDI TOF/TOF Mass SpectrometerS10OD030460 · OD · UNIVERSITY OF PENNSYLVANIA · PI PETERSSON, ERNEST JAMES · 2021 to 2021
$881k
NIGMS NIH HHS T32 GM133398NIH HHS S10 OD030460NINDS NIH HHS R01 NS103873NINDS NIH HHS R01 NS120625NINDS NIH HHS RF1 NS103873NINDS NIH HHS RF1 NS125770
6 · The paper itself

Abstract

Age-related neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD) are characterized by deposits of protein aggregates, or amyloid, in various regions of the brain. Historically, aggregation of a single protein was observed to be correlated with these different pathologies: tau in AD and α-synuclein (αS) in PD. However, there is increasing evidence that the pathologies of these two diseases overlap, and the individual proteins may even promote each other's aggregation. Both tau and αS are intrinsically disordered proteins (IDPs), lacking stable secondary and tertiary structure under physiological conditions. In this study we used a combination of biochemical and biophysical techniques to interrogate the interaction of tau with both soluble and fibrillar αS. Fluorescence correlation spectroscopy (FCS) was used to assess the interactions of specific domains of fluorescently labeled tau with full length and C-terminally truncated αS in both monomer and fibrillar forms. We found that full-length tau as well as individual tau domains interact with monomer αS weakly, but this interaction is much more pronounced with αS aggregates. αS aggregates also mildly slow the rate of tau aggregation, although not the final degree of aggregation. Our findings suggest that co-occurrence of tau and αS in disease are more likely to occur through monomer-fiber binding interactions, rather than monomer-monomer or co-aggregation.

Indexed as

alpha-Synucleintau ProteinsAlzheimer DiseaseAmyloidHumansParkinson DiseaseProtein AggregatesProtein Aggregation, PathologicalProtein BindingSpectrometry, Fluorescencealpha-SynucleinAmyloidProtein Aggregatestau Proteins

Identifiers

PMID39255305
PMCPMC11386428

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.